<DOC>
	<DOCNO>NCT02812940</DOCNO>
	<brief_summary>A phase II clinical study assess efficacy short-term everolimus prophylaxis Graft-versus-Host disease ( GvHD ) addition post-transplantation cyclophosphamide allogeneic hematopoietic stem cell transplantation patient haematological malignancy</brief_summary>
	<brief_title>Single-centre Study Everolimus GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT</brief_title>
	<detailed_description>Title clinical study : A single-centre study Certican ( everolimus ) Prophylaxis Graft-versus-Host Disease follow Post-Transplantation Cyclophosphamide Allogeneic Stem Cell Transplantation ( OCTET-EVER ) Indication : Patients haematological malignancy allogeneic haematopoietic stem cell transplantation match related unrelated donor follow reduce intensity condition post-transplantation cyclophosphamide Phase : Phase II clinical study Type study , study design , methodology : Single centre single arm clinical trial , A'Hern 's single stage phase II procedure Number subject : 20 ( 17 total evaluable ) Primary study objective To assess efficacy short-term everolimus GvHD prophylaxis addition post-transplantation cyclophosphamide allogeneic hematopoietic stem cell transplantation patient haematological malignancy describe influence modify immunosuppression concept incidence severity acute GvHD , relapse rate , minimal residual disease , immune reconstitution chimerism . Medical condition disease investigate : • Patients haematological malignancy allogeneic haematopoietic stem cell transplantation match related unrelated donor follow reduce intensity condition post-transplantation cyclophosphamide Name investigational medicinal product ( IMP ) : Everolimus ( Certican® ) Investigational medicinal product - dosage method administration : 1,5mg per o twice day ( target blood level 5 10ng/ml ) day +5 day +100 allogeneic stem cell transplantation Duration treatment : The treatment give day +5 day +100 allogeneic stem cell transplantation . The observation time last day +5 day +130 . Incidence chronic GvHD , overall survival relapse incidence record d+365 d+720 transplant .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients haematological malignancy allogeneic haematopoietic stem cell transplantation match related unrelated donor follow reduce intensity condition posttransplantation cyclophosphamide Principal inclusion criterion : • Written inform consent Known intolerance everolimus Presence history Microangiopathy Presence uncontrolled infection Severe organ dysfunction define : Cardiac leave ventricular ejection fraction ( LVEF ) less 35 % Diffusing lung capacity ( DLCO ) less 40 % Total lung capacity ( TLC ) less 40 % Forced expiratory volume ( FEV1 ) less 40 % Total bilirubin &gt; 3mg/dl Creatinineclearance less 40 ml/min Pregnancy breast feed Participation experimental drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>